Congress trades
BioNTech SE (BNTX)
About BioNTech SE
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Ugur Sahin
- Employees
- 7,807
- Listed since
- Oct 10, 2019
- Market value
- $24.7B
- Price to earnings
- -
- Earnings per share
- -$6.70
- Dividend yield
- -
www.biontech.com/de/de/home.html
Earnings
6 reported quarters · next on Nov 3, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 4, 2026 | -$3.70 | -$2.40 | $120.6M | $180.2M | EPS missRevenue miss |
| Q1 FY2026reported May 5, 2026 | -$2.43 | -$2.54 | $136.4M | $207.4M | EPS beatRevenue miss |
| Q4 FY2025reported Mar 10, 2026 | -$1.44 | -$0.22 | $1.1B | $902.3M | EPS missRevenue beat |
| Q3 FY2025reported Nov 3, 2025 | -$0.14 | -$1.12 | $1.8B | $843.7M | EPS beatRevenue beat |
| Q2 FY2025reported Aug 4, 2025 | -$1.82 | -$2.69 | $307.1M | $177.8M | EPS beatRevenue beat |
| May 5, 2025 | -$1.82 | -$2.48 | $200.4M | $215.1M | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| FMR LLC | $704.6M | 7,571,805 | +32.6% | 2.99% |
| Primecap Management Co | $351.0M | 3,772,031 | -0.6% | 1.49% |
| Dodge & Cox | $342.2M | 3,677,591 | +0.0% | 1.45% |
| Flossbach Von Storch AG | $207.1M | 2,226,138 | -39.5% | 0.88% |
| T. Rowe Price Investment Management, Inc. | $192.2M | 2,065,456 | -64.7% | 0.82% |
| Blackrock, Inc. | $172.6M | 1,854,966 | +11.9% | 0.73% |
| Temasek Holdings (Private) Ltd | $140.1M | 1,506,027 | 0.0% | 0.59% |
| BNP Paribas Arbitrage, Snc | $122.8M | 1,319,517 | -20.1% | 0.52% |
| Logos Global Management LP | $94.4M | 1,015,000 | +100.0% | 0.40% |
| GSK PLC | $82.8M | 889,824 | 0.0% | 0.35% |
| First Trust Advisors LP | $73.6M | 791,469 | -5.8% | 0.31% |
| Davern Capital Partners, LP | $70.2M | 754,550 | +147.3% | 0.30% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in BNTX
9 disclosures of 9 on record · median 30d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Val T. HoyleSpouse | Stock | Sale | $1,001 - $15,000 | -11.9%S&P +20.6% · vs S&P 500 -32.4% | Aug 7, 2025 | Sep 12, 2025 | 36d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +11.5%S&P +38.1% · vs S&P 500 -26.6% | Sep 3, 2024 | Oct 3, 2024 | 30d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +11.2%S&P +35.3% · vs S&P 500 -24.1% | Aug 30, 2024 | Sep 11, 2024 | 12d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | +11.7%S&P +51.2% · vs S&P 500 -39.5% | Apr 15, 2024 | May 15, 2024 | 30d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +5.6%S&P +48.1% · vs S&P 500 -42.5% | Mar 14, 2024 | Apr 7, 2024 | 24d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -3.2%S&P +67.7% · vs S&P 500 -70.9% | Dec 6, 2023 | Jan 7, 2024 | 32d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -3.7%S&P +66.4% · vs S&P 500 -70.1% | Dec 7, 2023 | Jan 7, 2024 | 31d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -0.6%S&P +67.0% · vs S&P 500 -67.6% | Dec 5, 2023 | Jan 7, 2024 | 33d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -37.0%S&P +71.4% · vs S&P 500 -108.4% | Jan 20, 2022 | Feb 8, 2022 | 19d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded BNTX?
Val T. Hoyle, Josh Gottheimer, Ro Khanna disclosed BNTX transactions in the filings shown here.
How quickly are BNTX trades disclosed?
Congressional disclosures took a median of 30 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.